Mobile

Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay imm...

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-005055-33

Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the present investigation is to compare the incidence or avoidance of corticosteroid use, as a measure of the decreased incidence of acute rejection episodes 6 and 12 months after primary renal transplantation in patients receiving three different immunosuppressive treatments. Current standard immunosuppression (group A: mycophenolate mofetil, tacrolimus and corticosteroids) will be compared to regimens with mycophenolate mofetil, daclizumab and a single week of corticosteroids as mainstay immunosuppression in combination with tacrolimus (group B) or (group C) where sirolimus, MMF and steroids will be continued.

Critère d'inclusion

  • renal transplantation

Liens